Hemlibra vs Ultomiris
Side-by-side cost comparison based on Medicare Part D data
Hemlibra
Emicizumab
Manufactured by Genentech/Roche
Ultomiris
Ravulizumab
Manufactured by Alexion
Hemlibra costs 48% less per claim than Ultomiris ($34,278.00 vs $65,292.00). A generic version of Hemlibra is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Hemlibra | Ultomiris |
|---|---|---|
| Avg Cost Per Claim | $34,278.00 | $65,292.00 |
| Total Medicare Spending | $1.2B | $1.6B |
| Total Beneficiaries | 4,200 | 4,800 |
| Total Claims | 36,000 | 24,000 |
| Annual Cost/Patient | $293,810.00 | $326,458.00 |
| Year-over-Year Change | +18.6% | +32.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Genentech/Roche | Alexion |
| Condition | Blood Disorders | Blood Disorders |
| Generic Name | Emicizumab | Ravulizumab |
Hemlibra vs Ultomiris: What the Data Shows
Hemlibra (Emicizumab) and Ultomiris (Ravulizumab) are both used to treat blood disorders. Based on Medicare Part D data, Hemlibra costs $34,278.00 per claim, which is 48% less than Ultomiris at $65,292.00 per claim.
Medicare spent $1.2B on Hemlibra and $1.6B on Ultomiris. In terms of patient reach, Ultomiris serves more beneficiaries (4,800 vs 4,200).
Year-over-year spending changed +18.6% for Hemlibra and +32.4% for Ultomiris. Hemlibra saw significant spending growth, suggesting increased utilization or price increases. Ultomiris saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Hemlibra is cheaper at $34,278.00 per claim, compared to $65,292.00 for Ultomiris. That makes Hemlibra about 48% less expensive per claim based on Medicare Part D data.
Yes, both Hemlibra and Ultomiris are used to treat blood disorders. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Emicizumab and generic Ravulizumab can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $1.2B on Hemlibra covering 4,200 beneficiaries, and $1.6B on Ultomiris covering 4,800 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.